Scientific Publications
Scientific Publications – latest research:
myLoop powered by CamAPS FX is a hybrid closed-loop system. CamAPS FX is designed and indicated for pregnancy and is a proven solution for all pediatric stages.
Learn more about the study data and how myLoop powered by CamAPS FX can make a difference for your patients with T1D.
Lee TTM, et al. Automated insulin delivery during the first 6 months postpartum (AiDAPT): a prespecified extension study. Lancet Diabetes Endocrinol. 2025 Mar;13(3):210-220. doi: 10.1016/S2213-8587(24)00340-1.
American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S282-S294. doi: 10.2337/dc24-S015.
Lawton J, et al.: Listening to Women: Experiences of Using Closed-Loop in Type 1 Diabetes Pregnancy. Diabetes Technol Ther. 2023 Dec;25(12):845-855. doi: 10.1089/dia.2023.0323.
Lee TTM, et al.: Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes. N Engl J Med. 2023 Oct 26;389(17):1566-1578. doi: 10.1056/NEJMoa2303911.
Benhalima K et al.: Management of type 1 diabetes in pregnancy: update onlifestyle, pharmacological treatment, and novel technologies for achieving glycaemic targets. Lancet DiabetesEndocrinol. 2023 Jul;11(7):490-508. doi: 10.1016/S2213-8587(23)00116-X. Erratum in: LancetDiabetes Endocrinol. 2023 Oct;11(10):e12. PMID: 37290466
Helen R, et al.: Randomized Trial of Automated Insulin Delivery in Pregnant Women with Type 1 Diabetes. Diabetes 20 June 2023; 72 (Supplement_1): 108–LB. doi: 10.2337/db23-108-LB
Lawton J, et al.: Healthcare professionals' views about how pregnant women can benefit from using a closed-loop system: Qualitative study. Diabet Med. 2023 May;40(5):e15072. doi: 10.1111/dme.15072.
Rankin D, et al.: Rollout of Closed-Loop Technology to Pregnant Women with Type 1 Diabetes: Healthcare Professionals' Views About Potential Challenges and Solutions. Diabetes Technol Ther. 2023 Apr;25(4):260-269. doi: 10.1089/dia.2022.0479.
Lee TTM, et al.: AiDAPT: automated insulin delivery amongst pregnant women with type 1 diabetes: a multicentre randomized controlled trial - study protocol. BMC Pregnancy Childbirth. 2022 Apr 5;22(1):282. doi: 10.1186/s12884-022-04543-z.
National Pregnancy in Diabetes (NPID) Audit Report 2020, England and Wales, 01 Jan 2019 to 31 Dec 2020; published on 14 Oct 2021: https://digital.nhs.uk/data-and-information/publications/statistical/national-pregnancy-in-diabetes-audit/2019-and-2020
Diabetes in pregnancy: management from preconception to the postnatal period. NICE guideline [NG3]. Published: 25 Feb 2015. Last updated: 16 Dec 2020. https://www.nice.org.uk/guidance/ng3/chapter/recommendations
Battelino T et al.: Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 1 August 2019; 42 (8): 1593–1603. doi: 10.2337/dci19-0028.
Feig DS et al: Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017 Nov 25;390(10110):2347-2359. doi: 10.1016/S0140-6736(17)32400-5. Epub 2017 Sep 15. Erratum in: Lancet. 2017 Nov 25;390(10110):2346. PMID: 28923465; PMCID: PMC5713979.
García-Patterson A et al.: Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction. Diabetologia 53, 446–451 (2010); 53: 446-51.
Ware J, et al. Eighteen-Month Hybrid Closed-Loop Use in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Trial. Diabetes Care. 2024 Oct 17:dc241313. doi: 10.2337/dc24-1313.
Ware J, et al. Effect of 48 Months of Closed-Loop Insulin Delivery on Residual C-Peptide Secretion and Glycemic Control in Newly Diagnosed Youth With Type 1 Diabetes: A Randomized Trial. Diabetes Care. 2024 Aug 1;47(8):1441-1448. doi: 10.2337/dc24-0360.
Madrid-Valero JJ et al.: Sleep Quality and Quantity in Caregivers of Children with Type 1 Diabetes Using Closed-Loop Insulin Delivery or a Sensor-Augmented Pump. Pediatric Diabetes. Vol 2023.
de Beaufort C, et al.: Cambridge Hybrid Closed-Loop System in Very Young Children With Type 1 Diabetes Reduces Caregivers' Fear of Hypoglycemia and Improves Their Well-Being. Diabetes Care. 2022 Sep 16;45(12):3050–3. doi: 10.2337/dc22-0693.
Kimbell B, et al.: Parents' views about healthcare professionals having real-time remote access to their young child's diabetes data: Qualitative study. Pediatr Diabetes. 2022 Sep;23(6):799-808. doi: 10.1111/pedi.13363.
Hart RI, et al.: Parents' experiences of using remote monitoring technology to manage type 1 diabetes in very young children during a clinical trial: Qualitative study. Diabet Med. 2022 Jul;39(7):e14828. doi: 10.1111/dme.14828.
Kimbell B, et al.: Parents' experiences of using a hybrid closed-loop system (CamAPS FX) to care for a very young child with type 1 diabetes: Qualitative study. Diabetes Res Clin Pract. 2022 May;187:109877.
doi: 10.1016/j.diabres.2022.109877.
Ware J. et al.: Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes. N Engl J Med. 2022 Jan;386(3):209-219. doi: 10.1056/NEJMoa2111673
Fattah M, et al.: Evaluating the Impact of Applying Personal Glucose Targets in a Closed-Loop System for People With Type 1 Diabetes. J Diabetes Sci Technol. 2024 May;18(3):695-700. doi: 10.1177/19322968221145184.
Tauschmann M. et al.: Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 2018 Oct;392(10155):1321-1329. doi: 10.1016/S0140-6736(18)31947-0
Barnard K. D. et al.: Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy. J Diabetes Sci Technol. 2017 Nov;11(6):1080-1088. doi: 10.1177/1932296817702656
Ware J, et al. Eighteen-Month Hybrid Closed-Loop Use in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Trial. Diabetes Care. 2024 Oct 17:dc241313. doi: 10.2337/dc24-1313.
Ware J, et al. Effect of 48 Months of Closed-Loop Insulin Delivery on Residual C-Peptide Secretion and Glycemic Control in Newly Diagnosed Youth With Type 1 Diabetes: A Randomized Trial. Diabetes Care. 2024 Aug 1;47(8):1441-1448. doi: 10.2337/dc24-0360.
Thabit H, et al.: Impact of hybrid closed-loop insulin delivery on cardiac rhythm in older adults with type 1 diabetes: A post hoc analysis of trial data. Diabetes Obes Metab. 2024 Mar;26(3):1105-1109. doi: 10.1111/dom.15366.
Lakshman R, et al.: Diabetic Ketoacidosis at Onset of Type 1 Diabetes and Glycemic Outcomes with Closed-Loop Insulin Delivery. Diabetes Technol Ther. 2024 Mar;26(3):198-202. doi: 10.1089/dia.2023.0307.
Haliloglu B, et al.: Postprandial Glucose Excursions with Ultra-Rapid Insulin Analogs in Hybrid Closed-Loop Therapy for Adults with Type 1 Diabetes. Diabetes Technol Ther. 2024 Feb 27. doi: 10.1089/dia.2023.0509.
Schneider-Utaka AK, et al.: Patient-reported outcomes for older adults on CamAPS FX closed loop system. Diabet Med. 2023 Sep;40(9):e15126. doi: 10.1111/dme.15126.
Alwan H, et al.: Time Spent in Hypoglycemia According to Age and Time of Day: Observations During Closed-Loop Insulin Delivery. Diabetes Technol Ther. 2023 Jul;25(7):485-491. doi: 10.1089/dia.2023.0061.
Thabit H, et al.: Impact of the CamAPS FX hybrid closed-loop insulin delivery system on sleep traits in older adults with type 1 diabetes. Diabetes Obes Metab. 2023 Mar;25(3):889-893. doi: 10.1111/dom.14914.
Hood KK, et al.: Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents. Diabetes Obes Metab. 2022 Dec;24(12):2309-2318. doi: 10.1111/dom.14815.
Boughton CK, et al.: Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes. N Engl J Med. 2022 Sep 8;387(10):882-893. doi: 10.1056/NEJMoa2203496.
Ware J. et al.: Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. The Lancet Digital Health. 2022 Apr;4(4):e245-e255. doi:10.1016/ S2589-7500(22)00020-6
Boughton CK, et al.: Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study. Lancet Healthy Longev. 2022 Mar;3(3):e135-e142. doi: 10.1016/S2666-7568(22)00005-8.
Rankin D, et al.: Adolescents' Experiences of Using a Smartphone Application Hosting a Closed-loop Algorithm to Manage Type 1 Diabetes in Everyday Life: Qualitative Study. J Diabetes Sci Technol. 2021 Sep;15(5):1042-1051. doi: 10.1177/1932296821994201.
Lawton J, et al.: Data Sharing While Using a Closed-Loop System: Qualitative Study of Adolescents' and Parents' Experiences and Views. Diabetes Technol Ther. 2021 Jul;23(7):500-507. doi: 10.1089/dia.2020.0637.
Chen NS, et al.: User Engagement With the CamAPS FX Hybrid Closed-Loop App According to Age and User Characteristics. Diabetes Care. 2021 Jul;44(7):e148-e150. doi: 10.2337/dc20-2762
Musolino G. et al.: Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes. Pediatr Diabetes. 2019 Sep;20(6):794-799. doi: 10.1111/pedi.12872
Musolino G, et al.: Assessing the efficacy, safety and utility of 6-month day-and-night automated closed-loop insulin delivery under free-living conditions compared with insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, multicentre, multinational, single-period, randomised, parallel group study protocol. BMJ Open. 2019 Jun 3;9(6):e027856. doi: 10.1136/bmjopen-2018-027856.
Alwan H, et al.: Real-World Evidence Analysis of a Hybrid Closed-Loop System. J Diabetes Sci Technol. 2023 Jul 8:19322968231185348. doi: 10.1177/19322968231185348.
Newman C, Hartnell S, Wilinska M, Alwan H, Hovorka R. Real-World Evidence of the Cambridge Hybrid Closed-Loop App With a Novel Real-Time Continuous Glucose Monitoring System. J Diabetes Sci Technol. 2023 Jul 28:19322968231187915. doi: 10.1177/19322968231187915.
Tseretopoulou X, et al.: Safe and effective use of a hybrid closed-loop system from diagnosis in children under 18 months with type 1 diabetes. Pediatr Diabetes. 2022 Feb;23(1):90-97. doi: 10.1111/pedi.13292.
Ware J, et al.: Safety of User-Initiated Intensification of Insulin Delivery Using Cambridge Hybrid Closed-Loop Algorithm. J Diabetes Sci Technol. 2024 Jul;18(4):882-888. doi: 10.1177/19322968221141924.
Nwokolo M, et al.: CamAPS FX Hybrid Closed-Loop with Ultra-Rapid Lispro Compared with Standard Lispro in Adults with Type 1 Diabetes: A Double-Blind, Randomized, Crossover Study. Diabetes Technol Ther. 2023 Dec;25(12):856-863. doi: 10.1089/dia.2023.0262.
Ware J, et al.: Hybrid Closed-Loop with Faster Insulin Aspart Compared with Standard Insulin Aspart in Very Young Children with Type 1 Diabetes: A Double-Blind, Multicenter, Randomized, Crossover Study. Diabetes Technol Ther. 2023 Jun;25(6):431-436. doi: 10.1089/dia.2023.0042.
Thabit H, et al.: Comparison of faster-acting aspart with insulin aspart under conditions mimicking underestimation or missed meal boluses in type 1 diabetes using closed-loop insulin delivery. Diabetes Obes Metab. 2023 Apr;25(4):1121-1124. doi: 10.1111/dom.14942.
Boughton CK, et al.: Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study. Diabetes Obes Metab. 2021 Jun;23(6):1389-1396. doi: 10.1111/dom.14355.
Related Content
You may also be interested in ...